Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

5,999JPY
2:00am EDT
Change (% chg)

¥-59 (-0.97%)
Prev Close
¥6,058
Open
¥6,059
Day's High
¥6,077
Day's Low
¥5,991
Volume
1,140,200
Avg. Vol
1,172,627
52-wk High
¥6,433
52-wk Low
¥4,537

Latest Key Developments (Source: Significant Developments)

Shionogi ‍announces positive top-line results for S-033188 phase 3 study
Monday, 24 Jul 2017 08:01am EDT 

July 24 (Reuters) - Shionogi & Co Ltd <4507.T>::Shionogi - ‍announces positive top-line results for s-033188 phase 3 study (capstone-1) in otherwise healthy influenza patients.Shionogi - ‍time to alleviation of symptoms (TTAS) was significantly reduced with s-033188 compared to placebo​.Shionogi & Co Ltd - ‍s-033188 was well tolerated​.Shionogi & Co Ltd - ‍based on results from capstone-1, shionogi plans to submit a new drug application (NDA) to PMDA in Japan later this year.  Full Article

Shionogi & lowers conversion price for 2019 due euro-yen denominated convertible bonds
Thursday, 22 Jun 2017 02:43am EDT 

June 22(Reuters) - Shionogi & Co Ltd <4507.T>:Says it lowers the conversion price for 2019 due euro-yen denominated convertible bonds to 4,150.9 yen per share, from 4,167.5 yen per share, effective April 1.  Full Article

PeptiDream announces licensing of peptide discovery platform system (PDPS) technology to Shionogi
Monday, 12 Jun 2017 03:22am EDT 

June 12(Reuters) - PeptiDream Inc <4587.T>:Says it has entered into a technology license agreement with Osaka-based Shionogi & Co Ltd <<<4507.T>>>, to nonexclusively license PeptiDream’s proprietary Peptide discovery platform system (PDPS) technology.Under the terms of the agreement, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology.  Full Article

GSK says ViiV Healthcare submits 2-drug HIV regimen application to EMA,U.S. FDA
Friday, 2 Jun 2017 02:00am EDT 

June 2 (Reuters) - Glaxosmithkline Plc ::ViiV submits first 2-drug hiv regimen application.‍Priority review voucher submitted in US with anticipated target action date of 6 months​.‍EU and US submissions for single tablet combining dolutegravir and rilpivirine​.‍$130 million cost of voucher will be reported as an research and development expense in GSK's q2 2017 adjusted results​.Under prescription drug user fee act, anticipated target action date is six months after receipt of application by FDA.Use of dolutegravir and rilpivirine as a two-drug regimen for hiv-1 maintenance therapy is investigational and not approved anywhere in world.  Full Article

Sekisui Chemical to set up JV for research and commercial manufacture of peptide pharmaceuticals
Thursday, 1 Jun 2017 04:45am EDT 

June 1 (Reuters) - Sekisui Chemical Co Ltd <4204.T>:* Says it plans to set up JV, for the research and commercial manufacture of peptide pharmaceuticals with PeptiDream Inc <4587.T> and Shionogi & Co Ltd <4507.T>.* Other details remain to be decided later .  Full Article

R&I affirms Shionogi & Co Ltd's rating at "A+" and announces stable outlook – R&I
Thursday, 19 Jan 2017 01:00am EST 

Shionogi & Co Ltd <4507.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" – R&I .Rating outlook stable– R&I.  Full Article

Shionogi & retires 22 mln treasury shares on Jan. 10
Tuesday, 10 Jan 2017 01:09am EST 

Shionogi & Co Ltd <4507.T>: Says the co retired 22 million shares(6.3 percent stake) of its common stock on Jan. 10 .Says the total shares outstanding is 329.1 million shares after the retirement.  Full Article

Shionogi to set up new units
Wednesday, 21 Dec 2016 12:18am EST 

Shionogi & Co Ltd <4507.T>: Says it will have new units on April 3, 2017 . Says new units will with name of Shionogi Administration Service Company Limited, Shionogi Career Development Center Company Limited, Shionogi Digital Science Company Limited, Shionogi Business Partner Company Limited, Shionogi Pharmacovigilance Center Company Limited, and Shionogi Marketing Solutions Company Limited .Says every new unit will be capitalized at 10 million yen respectively.  Full Article

Shionogi & Co says sales transfer of 21 product and tansfer of manufacturing and marketing approval
Monday, 1 Aug 2016 10:58pm EDT 

Shionogi & Co Ltd <4507.T>: Says it to transfer sale of 21 products on Dec. 1 and manufacturing and marketing approval after 2017 to Kyowa Pharmaceutical Industry Co., Ltd. .Says Kyowa Pharmaceutical Industry Co., Ltd. to pay 15.4 billion yen to the co on Dec. 1 for the sales transfer of 21 products.  Full Article

Lupin buys Japan's Shionogi's product portfolio<4507.T>
Monday, 1 Aug 2016 10:53pm EDT 

Lupin Ltd : Acquires branded product portfolio from Shionogi in Japan . To acquire 21 long-listed products from Shionogi & Co .  Full Article

BRIEF-Shionogi ‍announces positive top-line results for S-033188 phase 3 study

* Shionogi - ‍announces positive top-line results for s-033188 phase 3 study (capstone-1) in otherwise healthy influenza patients